Sei Investments Co. Has $94.59 Million Stock Position in Novartis AG $NVS

Sei Investments Co. lifted its position in Novartis AG (NYSE:NVS) by 9.6% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 619,274 shares of the company’s stock after buying an additional 54,262 shares during the period. Sei Investments Co.’s holdings in Novartis were worth $94,594,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. J.W. Cole Advisors Inc. lifted its holdings in Novartis by 0.6% during the fourth quarter. J.W. Cole Advisors Inc. now owns 10,577 shares of the company’s stock worth $1,348,000 after acquiring an additional 64 shares in the last quarter. Roundview Capital LLC grew its stake in Novartis by 2.5% in the fourth quarter. Roundview Capital LLC now owns 2,711 shares of the company’s stock valued at $374,000 after acquiring an additional 66 shares during the period. IMA Advisory Services Inc. increased its holdings in shares of Novartis by 10.9% in the fourth quarter. IMA Advisory Services Inc. now owns 710 shares of the company’s stock worth $98,000 after acquiring an additional 70 shares in the last quarter. Abundance Wealth Counselors increased its holdings in shares of Novartis by 0.4% in the fourth quarter. Abundance Wealth Counselors now owns 16,927 shares of the company’s stock worth $2,334,000 after acquiring an additional 73 shares in the last quarter. Finally, Atlantic Edge Private Wealth Management LLC raised its position in shares of Novartis by 3.5% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 2,230 shares of the company’s stock worth $307,000 after purchasing an additional 75 shares during the period. Institutional investors and hedge funds own 13.12% of the company’s stock.

Novartis Stock Down 0.8%

NVS stock opened at $154.84 on Friday. The company has a market cap of $295.46 billion, a price-to-earnings ratio of 23.35, a P/E/G ratio of 2.69 and a beta of 0.45. Novartis AG has a twelve month low of $112.34 and a twelve month high of $170.46. The business has a 50 day moving average price of $151.95 and a two-hundred day moving average price of $152.13. The company has a quick ratio of 0.65, a current ratio of 0.86 and a debt-to-equity ratio of 0.89.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Tuesday, June 30th. The company reported $2.41 earnings per share (EPS) for the quarter. The company had revenue of $14.95 billion for the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%. Analysts anticipate that Novartis AG will post 8.78 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on NVS shares. Weiss Ratings cut Novartis from a “buy (a-)” rating to a “buy (b)” rating in a report on Wednesday, April 29th. Citigroup reissued a “buy” rating on shares of Novartis in a research note on Wednesday. Seven analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Novartis currently has a consensus rating of “Hold” and an average price target of $141.20.

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.